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Abstract
Background: The objectives of this study are to assess Canadian ophthalmologists’ awareness of established uveitis
treatment guidelines and clinical management of uveitis and to assess the frequency of government applications
for immunomodulatory therapy (IMT) and identify primary prescribers.
A 25-item questionnaire was sent to 759 practicing Canadian ophthalmologists. Six questions assessed
demographics including the year of residency completion, training by uveitis specialists during residency, and
fellowship training. Five questions assessed application of guidelines to clinical scenarios, and 12 questions assessed
referral patterns and success of obtaining coverage for IMT.
Results: Of 144 respondents, 12 (8.3 %) were uveitis specialists; 45.1 % of respondents had uveitis training during
residency by a uveitis specialist. Sixty-one percent reported awareness of management guidelines. Recent graduates
(2001–2012) referred patients to uveitis specialists (55.3 %) less frequently than earlier graduates. Recent graduates
also managed uveitis patients more frequently with corticosteroid injections (15.6 %) than those who graduated
before 1980 (9.75 %). The majority (93.6 %) of respondents submitted less than six IMT funding applications for
provincial drug coverage yearly, and 5.5 % reported prescribing IMT themselves, rather than referring to other specialists.
Conclusions: Although greater than half of respondents reported awareness of uveitis treatment guidelines,
Canadian ophthalmologists’ awareness of uveitis treatment guidelines and application of the guidelines to
patient care could be improved. Few applications are made for IMT, and the majority of applications are sent by
non-ophthalmologists. This suggests the need for further education of ophthalmologist about uveitis treatment
guidelines and for more ophthalmologists trained to manage uveitis with IMT.
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Background
Uveitis, a group of ocular inflammatory conditions, ac-
counts for 10 to 15 % of blindness in developed countries
[1, 2]. As per standard nomenclature, chronic uveitis is de-
fined as persistent uveitis characterized by prompt relapse
(in less than 3 months) after discontinuation of therapy
[3]. Persistent uveitis is defined as inflammation greater
than 3 months in duration [3]. Recurrent uveitis is re-
peated episodes of uveitis separated by periods of inactiv-
ity without treatment, in which these periods of inactivity
without treatment are at least 3 months in duration [3].
Sight-threatening disease arises from chronic, persistent,
or recurrent inflammation. Left untreated or undertreated,
chronic, persistent, or recurrent inflammation may lead
to complications, such as cataract, glaucoma, macular
edema, retinal or choroidal inflammation and atrophy,
intraocular hemorrhage, or optic nerve atrophy. The
therapeutic goal is to prevent vision loss from these com-
plications by controlling or eliminating chronic, persistent,
or recurrent inflammation. Systemic corticosteroid and lo-
cally administered corticosteroid injections treat ocular in-
flammation during acute episodes of uveitis, but the side
effects of multiple pulse treatments or prolonged systemic
corticosteroid administration limit their convenience as
monotherapy for chronic and persistent uveitis, except in
selected cases where dexamethasone or fluocinolone
implants have been shown to be successful as mono-
therapy [4]. Persistent or chronic cases of uveitis, where
corticosteroid therapy has failed to adequately treat dis-
ease, require long-term immunomodulatory therapy
(IMT) to treat active inflammation and reduce the fre-
quency of recurrences [5]. The uveitis management guide-
lines developed by an international panel of experts
recommends the initiation of corticosteroid-sparing
IMT if intraocular inflammation cannot be controlled
with <10 mg/day of prednisone within 3 months [5].
However, in the recent survey of uveitis treatment pat-
terns in the USA, Nguyen et al. showed that 75 % of
the physician cohort surveyed was not aware of the
aforementioned management guidelines [6]. The survey
also indicated that the average corticosteroid dose was
44 mg/day and this dose was maintained for an average
duration of 21 months, which is much higher than the rec-
ommended tapered doses of corticosteroids to <10 mg/day
within 3 months [5]. The high doses of corticosteroid con-
tributed to the significant adverse effects observed in the
cohort of uveitis patients in the survey. Therefore, more
widespread awareness of the uveitis treatment guidelines,
leading to less reliance on corticosteroids, and appropriate
timing of corticosteroid-sparing IMT would likely improve
patient outcomes.
The purpose of this study is to assess, among Canadian
ophthalmologists, the current awareness of published
guidelines for the treatment of uveitis and to evaluate
whether practice patterns are congruent with the published
uveitis treatment guidelines. This study also assessed the
frequency of applications to the government and private
insurance providers for immunomodulatory drugs or
biologics.
Methods
Survey population and development
The study was approved by the Ottawa Health Science
Network Research Ethics Board. A 25-item questionnaire
was developed by the authors and distributed electronic-
ally to 759 practicing Canadian ophthalmologists via the
Canadian Ophthalmological Society (COS). Residents and
fellows were not included in this study. Informed consent
was implied with the completion and electronic submis-
sion of the survey. No remuneration was given to respon-
dents. Data was collected over a 4-month period from
August 2012 to November 2012.
The following data were collected: the year of residency
completion, presence of a uveitis specialist at the respon-
dent’s center of residency training, fellowship training in
uveitis, and other sub-specialities including pediatric
ophthalmology, retina, anterior segment and others, and
percentage of patients with uveitis in the respondent’s
practice. Practice pattern data was also collected. This
included awareness and utilization of uveitis treatment
guidelines, referral patterns and associated barriers to
referrals, co-management of uveitis with uveitis specialists
or non-ophthalmologists, number of IMT applications for
provincial and private insurance drug coverage, and
success of obtaining IMT from these providers. Under-
standing and application of the aforementioned uveitis
treatment guidelines was assessed by survey questions
comprising definitions and clinical scenarios (Additional
file 1).
Data analysis
Demographic and other data were tabulated. The propor-
tion of total correct responses to the clinical scenario ques-
tions was defined as the proportion of cumulative correct
responses to each question. Non-responses were not in-
cluded in the proportions. Descriptive analyses were
conducted where appropriate, and confidence interval
(CI) for proportions was calculated using the exact
method.
Statistical analysis was performed using SAS software
(SAS Institute Inc., Cary, NC). Analyses were considered
to be significant if p < 0.05; reported p values were not
adjusted for multiple testings and should be considered
nominal. Use of Fisher’s exact test and chi-squared test
was based on sample sizes. Fisher’s exact test was used
to determine whether awareness of uveitis management
guidelines differed according to the following training
circumstances: (1) sub-specialty training, (2) fellowship
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training in uveitis, and (3) presence of a uveitis specialist
at the respondents’ center of residency training. Chi-
squared test was used in the comparison of the proportion
of total correct responses to clinical scenario questions to
the following variables: (1) sub-specialty training, (2) fellow-
ship training in uveitis, and (3) presence of a uveitis special-
ist at the respondents’ center of residency training.
The year of residency completion was categorized into
three groups: (1) 1960 to 1980, (2) 1981 to 2000, and (3)
2001 to 2012. Multivariate analysis was used to determine
whether the year of residency completion was associated
with the proportion of total correct responses to clinical
scenario questions. Descriptive analyses were used to
compare the year of residency completion with the fre-
quency of selecting “corticosteroid injections” as response
to clinical scenario questions and frequency of referral to
uveitis specialists.
Results
The response rate of the survey was 19.23 % (146/759),
and 87.7 % (128/146) of respondents completed the sur-
vey in its entirety. Demographic and referral pattern data
are detailed in Table 1. Among the respondents, 8.3 %
(12/146; CI = 0.04–0.14) were uveitis specialists. A fellowship-
trained uveitis specialist was present at 45.8 % (66/148;
CI = 0.36–0.53) of the respondents’ center of residency
training. Overall, 93.8 % (137/146; CI = 0.89–0.97) of
the physicians’ practices consisted of less than 30 % of
uveitis patients. The majority of respondents (73.3 %,
107/146; CI = 0.65–0.80) indicated they have referred
patients to uveitis specialists.
Self-reported awareness of the uveitis management
guidelines was 61.0 % (89/146; CI = 0.53–0.69), and 51.7 %
(74/143; 3 no responses; CI = 0.43–0.60) of respondents
indicated the utilization of these guidelines. The pro-
portion of total correct responses to the clinical scenario
questions was not statistically different (p = 0.547) between
physicians who reported awareness of the aforementioned
guidelines and those who did not. Awareness of guidelines
did not differ significantly between respondents who
were trained in uveitis (p = 0.127), respondents with
sub-speciality training (p = 0.179), and presence of a
fellowship-trained uveitis specialist at the respondent’s
center of residency training (p = 0.232) (Table 2).
Adherence to the uveitis management guideline rec-
ommendations [1] was evaluated using clinical scenario
questions. The association between adherence to guide-
lines and different training circumstances was assessed.
A statistically significant difference in the proportion of
total correct responses to clinical scenario questions was
also found between those with fellowship training in
sub-specialities and those with no fellowship training
(p = 0.0145). However, the proportion of total correct
responses to the clinical scenario questions was not
Table 1 Demographics and referral pattern data of respondents
Question n (%) CI
Type of clinical practice
Community practice 91 (63.2) 0.55–0.71
Part-time academic 21 (14.6) 0.09–0.21
Full-time academic 32 (22.2) 0.16–0.30
No response 2
Year of ophthalmology residency completion
1960–1970 7 (4.8) 0.02–0.09
1971–1980 23 (15.8) 0.10–0.23
1981–1990 43 (29.5) 0.22–0.37
1991–2000 34 (23.3) 0.17–0.31
2001–2012 39 (26.7) 0.18–0.35
No response 0
Sub-specialty or fellowship training
No fellowship training 67 (45.9) 0.35–0.51
Retina 24 (16.4) 0.10–0.22
Pediatrics 11 (7.5) 0.04–0.12
Uveitis 12 (8.2) 0.04–0.13
Cornea/anterior segment 15 (10.3) 0.05–0.15
Other 27 (18.5) 0.12–0.24
No response 0
Fellowship-trained uveitis specialist present at the respondents’ center
of residency training
Yes 66 (45.8) 0.37–0.54
No 78 (54.2) 0.46–0.62
No response 2 (1.37)
Percentage of patients with uveitis in respondents’ clinical practice
>60 % 2 (1.4) 0.002–0.05
30–60 % 7 (4.8) 0.02–0.09
<30 % 137 (93.8) 0.89–0.97
No response 0
Referral to uveitis specialists
Yes 107 (73.3) 0.65–0.80
No 27 (18.5) 0.13–0.26
Respondent is a uveitis specialist 12 (8.2) 0.04–0.14
No response 0
Barriers of referral encountered when referring patients to uveitis
specialist
Geography (distance) 38 (32.2) 0.19–0.34
Wait time 46 (39.0) 0.24–0.39
None 40 (33.9) 0.20–0.35
Not application. Care for patients with uveitis 15 (12.7) 0.06–0.16
Other 8 (6.78) 0.02–0.10
No response 28
n number of respondents
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statistically significant across the following groups of
comparisons: whether the respondent had fellowship
training in uveitis (p = 0.0509) and whether a uveitis
specialist was present at the respondent’s center of resi-
dency (p = 0.698) (Table 3).
The year of residency completion was categorized into
three groups: 1960 to 1980, 1981 to 2000, and 2001 to
2012. The proportion of total correct responses to clinical
scenario questions in association with the year of resi-
dency completion is detailed in Table 3. When comparing
the proportion of total correct responses in clinical sce-
nario questions to the year of residency completion, there
was a statistically significant difference between respon-
dents who completed residency during 2000 to 2012 and
those during 1960 to 1981 (p = 0.0208) and 1981 to 2000
(p = 0.0067). The selection of corticosteroid injections
(intravitreal or periocular) in the clinical scenario ques-
tions, which was an incorrect response, was 7.1 %
among graduates from 1960 to 1980, 12.4 % in gradu-
ates from 1981 to 2000, and 15.6 % in graduates from
2001 to 2012. Referral to a uveitis specialist was 90.0 %
(27/30; CI = 0.73–0.98) among those who completed
residency during 1960 to 1980, 76.6 % (59/77; CI =
0.63–0.83) for graduates in 1981 to 2000, and 53.8 %
(21/39; CI = 0.37–0.70) in 2001 to 2012 (Fig. 1).
The frequency of IMT applications and success of
obtaining IMT are shown in Table 4. When IMTs are re-
quired, 5.5 % of physicians (8/145; 1 no response; CI =
0.02–0.11) would prescribe the IMT themselves, while
54.5 % (79/145; CI = 0.46–0.63) would seek prescription
of the IMT from a rheumatologist, dermatologist, or
general internist, and 40.0 % (58/145; CI = 0.32–0.48)
would refer to an ophthalmologist to coordinate the acqui-
sition of IMT. Overall, 93.6 % (117/125; 21 no responses;
CI = 0.88–0.97) of physicians make less than six IMT appli-
cations per year, and 89.0 % (105/118; 28 no responses) of
respondents make less than six co-IMT applications with
rheumatologists or other physicians. Less than 10 % of
IMT applications was successfully obtained through private
insurance and provincial drug coverage among 64.0 % of
physicians (71/111; 35 no responses; CI = 0.54–0.73) and
56.5 % of physicians (61/108; 38 no responses; CI = 0.47–
0.66), respectively. The frequency of IMT applications
was 25.0 % (17/68; 78 no responses; CI = 0.15–0.37) for
Table 2 Awareness of uveitis management guidelines in association with different training circumstances
Awareness of treatment guidelines Aware, n (%) Not aware, n (%) p value CI
Stratified by the presence of a fellowship-trained uveitis
specialist at the center of residency training
89 (50.0 %) 57 (39.3) 0.232 −0.057 to 0.26
Stratified by fellowship training in uveitis 10 (83.30 %) 2 (16.70 %) 0.127 NA, n < 5
Stratified by fellowship training in a related sub-specialty 50 (64.96 %) 27 (35.06 %) 0.179 −0.05 to 0.28
n number of respondents, CI confidence interval, NA not applicable
Table 3 Total response rate to uveitis management questions in association with awareness of treatment guidelines, different





95 % Confidence interval p value
Awareness of uveitis treatment guidelines
Aware 406 242 (59.61) 0.55–0.64 0.5471
Not aware 243 129 (53.09) 0.47–0.59
Fellowship training
Fellowship training 348 189 (54.31) 0.49–0.60 0.0145
No fellowship training 301 192 (63.79) 0.58–0.69
Uveitis fellowship training
Uveitis-trained 56 26 (46.43) 0.33–0.60 0.0509
No uveitis training 593 355 (59.87) 0.56–0.64
Uveitis specialist present at the center of the respondents’ residency training
Uveitis specialist present 288 166 (57.64) 0.52–0.63 0.6981
No uveitis specialist present 355 210 (59.15) 0.54–0.64
Year of residency completion
1960–1980 131 84 (64.12) 0.55–0.72 1981–2000 vs 1960–1980: 0.3596
1981–2000 352 214 (60.80) 0.55–0.66 2001–2012 vs 1981–2000: 0.0208
2001–2012 166 83 (50) 0.42–0.58 2001–2012 vs 1960–1980: 0.0067
vs versus
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mycophenolate mofetil, 38.2 % (26/68; CI = 0.27–0.51)
for cyclosporine, 32.4 % (22/68; CI = 0.22–0.45) for
anti-tumor necrosis factor (TNF), and 36.8 % (25/68;
CI = 0.25–0.49) for others.
Discussion
Despite the well-recognized adverse effects of long-term
corticosteroid usage, it has been the mainstay of uveitis
management since its development [5, 7]. In addition to
concerns about their adverse effects, high-dose systemic
or locally injected corticosteroids, particularly serial perio-
cular or intraocular corticosteroid injections, are not an
optimal management strategy for chronic or frequently re-
current uveitis. At the time of writing, no Health Canada-
approved immunomodulatory drugs are indicated for
uveitis and all such drugs are used off-label. A sustained-
release dexamethasone intravitreal implant (Ozurdex; Aller-
gan, Inc., Irvine, CA, USA) and Retisert (Bausch&Lomb,
Rochester, NY, USA) are currently the only Health Canada-
approved treatments for uveitis. However, these implants
are only indicated for posterior uveitis and not anterior
or intermediate uveitis [5]. Although studies have dem-
onstrated the effectiveness of Ozurdex for non-infectious
posterior uveitis, the protracted disease course of some
patients with chronic uveitis, measured in years and de-
cades, is lengthy compared to the 6-month duration of
a steroid implant [8]. When treatment with systemic
corticosteroid and/or multiple local injections or implants
have failed to reduce intraocular inflammation to an
acceptable level, then corticosteroid-sparing IMT is
warranted. An international expert panel has published
guidelines recommending the appropriate initiation of
corticosteroid-sparing IMT. [5]
To the best our knowledge, this is the first study exam-
ining the awareness of and adherence to uveitis manage-
ment guidelines among Canadian ophthalmologists. This
study described the awareness and utilization of the afore-
mentioned guidelines, practice pattern variations across
different years of residency completion, and the fre-
quency of prescribing IMT and co-management of uve-
itis patients.
Awareness of and adherence to uveitis management
guidelines
In this survey, self-reported awareness of the uveitis
management guidelines was 61.0 % (CI = 0.53–0.69) and
51.7 % (CI = 0.43–0.60) of respondents indicated utilization
of these guidelines. The level of awareness of the aforemen-
tioned guidelines found in this study is higher than those
found by Nguyen et al., where 25 % of the US physician co-
hort surveyed was aware of the aforementioned manage-
ment guidelines [4, 5]. In addition, the results of this survey
showed that self-reported awareness of guidelines was not
associated with significantly higher proportion of total cor-
rect responses to the clinical scenario questions (p = 0.547),
suggesting that ophthalmologists who reported awareness
of the uveitis management guidelines did not use the guide-
lines in their clinical practice.
Factors which influence respondents’ awareness of treat-
ment guidelines were assessed. Awareness and unawareness
of guidelines did not differ significantly for respondents
who were trained in uveitis (p = 0.127), respondents
with any sub-speciality training (p = 0.179), and presence
of fellowship-trained uveitis speciality at the respondent’s
center of residency training (p = 0.232) (Table 2). These
cumulative results suggest that awareness of published
recommendations was not affected by sub-specialty train-
ing (including uveitis training) or residency training by a
uveitis specialist. Despite the large difference observed be-
tween self-reported awareness (83.30 %; CI not applicable)
and unawareness (16.70 %; CI not applicable) of man-
agement guidelines among the uveitis specialists, no
statistically significant difference was found. This may
be attributable to inadequate power of the analysis due
to the small number of uveitis specialists (12) who
responded to this survey.
0 20 40 60 80 10
0
% of correct responses
Referral to uveitis specialist 
Treat with corticosteriod injections


















Fig. 1 The year of residency completion in association with the (a) proportion of total correct responses to clinical scenario questions (p = 0.0208
for 2001–2012 vs 1981–2000; p = 0.0067 for 2001–2012 vs 1960–1980), (b) frequency of referral to uveitis specialists, and (c) frequency of managing
patients with corticosteroid injections in clinical scenario questions
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Table 4 Immunomodulatory therapy applications to public and private insurance providers
Question n (%) 95 % CI
How do you obtain immunomodulatory drugs or biologics for your patients?
Request from a rheumatologist, dermatologist, gastroenterologist, or internist 79 (54.5) 0.46–0.62
Refer to an ophthalmologist who will prescribe or coordinate further care for patients with uveitis 58 (40.0) 0.32–0.48
Prescribe yourself 8 (5.5) 0.02–0.11
No response 1
Refer patients to a uveitis specialist
Yes 107 (73.3) 0.65–0.80
No 27 (18.5) 0.13–0.26
I am a uveitis specialist 12 (8.2) 0.04–0.14
No response 0
Number of new applications made to the government per year for IMT coverage
0–5 117 (93.6) 0.88–0.97
6–10 5 (4.0) 0.01–0.09
11–20 2 (1.6) 0.002–0.06
21–30 1 (0.8) 0.0002–0.04
>30 0
No response 21
Number of co-applications for IMT made with rheumatologists or other physicians
0–5 105 (89.0) 0.69–0.84
6–10 10 (8.5) 0.03–0.13
11–20 2 (1.7) 0.002–0.05
21–30 0 0.00–0.03
>30 1 (0.8) 0.002–0.04
No response 28
Percentage of respondent’s patients with their IMT successfully covered through government or provincial health plan
<10 % 71 (64.0) 0.54–0.73
10–50 % 32 (28.8) 0.21–0.38
51–90 % 5 (4.5) 0.02–0.10
>91 % 3 (2.7) 0.006–0.08
No response 35
Percentage of respondent’s patients with their IMT successfully covered through private insurance
<10 % 61 (56.5) 0.46–0.66
10–50 % 29 (26.9) 0.19–0.36
51–90 % 10 (9.3) 0.04–0.16
>91 % 8 (7.4) 0.03–0.14
No response 38
Class of IMT applied through the Exceptional Access Program
Mycophenolate mofetil 17 (25.0) 0.11–0.28
Anti-TNF 22 (32.4) 0.16–0.35
Cyclosporine 26 (38.2) 0.20–0.39
Others 25 (36.8) 0.19–0.38
No response
IMT immunomodulatory therapy, TNF tumor necrosis factor
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The associations between adherence to guidelines and
different training circumstances were assessed. Adher-
ence to guideline recommendations was determined by
the proportion of total correct responses to clinical sce-
nario questions. The proportion of total correct responses
was significantly lower for respondents who had previous
sub-specialty fellowship training than those who did not
(p = 0.0145), suggesting that respondents with compre-
hensive ophthalmology practices were more likely to cor-
rectly identify cases where referral for IMT is necessary.
Initially, this finding appears to contradict our hypothesis
that additional fellowship training may be associated with
higher likelihood of correctly identifying responses in clin-
ical scenario questions. This apparent inconsistency may
be due to the complexity of the cases presented in the
clinical scenario questions, which focused on the manage-
ment of chronic or recurrent uveitis. Multiple studies have
shown that community-based comprehensive ophthalmol-
ogists manage a greater proportion of anterior uveitis and
responsive uveitis cases than the ophthalmologists in uni-
versity referral centers [9–11]. Uveitis cases which are
refractory to treatment or chronic are more frequently
managed by university-based ophthalmologists, most
frequently uveitis specialists [9–11]. Since community-
based ophthalmologists are more likely to refer treatment-
refractory patients to specialists, this may explain the
greater proportion of total correct responses observed in
this study.
In contrast, the proportion of total correct responses
was not significantly different between uveitis specialists
and those without uveitis fellowship training (p = 0.0509).
This analysis may not be accurate due to the limited num-
ber of uveitis specialists included in this study, and as
such, the results are inconclusive. The proportion of total
correct responses was also not significantly higher be-
tween respondents who had a uveitis specialist present at
the academic center where they completed residency
training and those who did not (p = 0.6981). As such, oph-
thalmology residents may have limited interactions with
these specialists.
Uveitis management patterns among the most recent
graduates
The year of residency completion was associated with a
lower proportion of total correct responses. In particular,
the most recent graduates (i.e., completed residency be-
tween 2001 and 2012) were less likely to correctly answer
the clinical scenario questions compared to respondents
who completed residency from 1960 to 1980 (p = 0.0067)
and from 1981 to 2000 (p = 0.0208). This suggests the
most recent graduates were less likely to correctly identify
uveitis cases where IMT induction is necessary based on
the management guidelines [5]. In the 2008 Canadian sur-
vey evaluating residents and recent graduates’ perception
of competencies in different areas of clinical training,
the sub-specialties where most respondents reported in-
sufficient exposure were low-vision rehabilitation (77.5 %),
refraction and glasses prescription (65 %), and neuro-
ophthalmology (45 %); only approximately 15 % of re-
spondents indicated that clinical exposure to uveitis
was inadequate in achieving competency [12]. The study
by Zhou et al. described “adequate clinical exposure”
broadly and did not specify exposures to investigations,
diagnosis, or management strategies [12]. In contrast, the
clinical scenario question in this survey focused on uveitis
management, particularly the appropriate initiation of
corticosteroid-sparing IMT and appropriate timing of
referral to a uveitis specialist for chronic uveitis man-
agement. Nonetheless, the discrepancy between recent
graduates’ perception of competence in uveitis and their
lower proportion of correct responses to clinical scenario
questions suggests the importance of raising awareness of
uveitis management guidelines in Canadian residency
programs.
Self-reported referral rate to a uveitis specialist was the
lowest among the most recent graduates (53.8 %; CI =
0.37–0.70) compared to those who completed residency
during 1960 and 1980 (90.0 %; CI = 0.73–0.98) and during
1981 to 2000 (76.6 %; CI = 0.66–0.85). The lower rate of
referrals among newer graduates found in this survey par-
allels the results of the 2004 Canadian National Uveitis
Survey [13]. In addition to differences in the proportion of
referrals, recent graduates were also more likely to man-
age IMT-requiring uveitis with off-label corticosteroid in-
jections. This observation may be attributable to the rapid
increase of intravitreal injections performed for posterior
segment diseases in the past decade [14, 15]. In this case,
the increased likelihood to treat uveitis with corticosteroid
injections among the most recent graduates may contrib-
ute to the lower proportion of referrals observed.
Applications for immunomodulatory therapy coverage to
provincial drug coverage and private providers
Immunomodulatory agents are indicated for corticosteroid-
sparing in patients with recurrent or chronic ocular in-
flammation where the dose of systemic corticosteroid
is ≥10 mg/day or ≥0.1 mg/kg/day and duration of cor-
ticosteroid therapy is ≥3 months [5, 16]. The adverse
effects of corticosteroid therapy have been shown to be
more frequent than IMT [17, 18]. However, many oph-
thalmologists do not have extensive training in IMT
administration, and monitoring and collaboration with
uveitis specialists, rheumatologists, or internists is ne-
cessary [4]. Our results showed that only 5.5 % (CI =
0.02–0.11) of physicians would prescribe IMT themselves
and 93.6 % (CI = 0.88–0.97) make less than six IMT appli-
cations for provincial and private provider drug coverage
per year. Thus, IMT initiation by ophthalmologists is
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infrequent. When IMT is required, 54.5 % (CI = 0.46–
0.63) of respondents would coordinate IMT acquisition
with specialists such as rheumatologists, dermatologists,
or general internists. However, 89.0 % (CI = 0.82–0.94) of
respondents make less than six co-applications for IMT
with rheumatologists or other physicians. Cumulatively,
these results suggest that ophthalmologists make few IMT
applications themselves and co-application with other
physicians and majority of IMT applications are sent by
non-ophthalmologists.
Over 73 % (CI = 0.65–0.80) of respondents stated that
they refer patients to uveitis specialists. When IMT ini-
tiation is required, 40.0 % (CI = 0.32–0.48) of physicians
would refer patients to uveitis specialists. Although ma-
jority of respondents refer patients to uveitis specialists,
they also frequently identified geographic distance
(32.2 %; CI = 0.24–0.41)) and wait time (39.0 %; CI =
0.30–0.48) as barriers. These barriers to referral may
delay the initiation of IMT and result in further vision
loss secondary to persistent ocular inflammation. Given
the limitations of timely access to uveitis specialists, co-
ordinating the acquisition of IMT with other specialists
such as rheumatologists and internists is essential. Yet,
the low number of co-IMT applications (fewer than six)
made by ophthalmologists with other physicians is
concerning.
The uveitis management guidelines outline the circum-
stances in which IMT induction is necessary [5]. However,
there is limited information available on which IMT is
considered first-line corticosteroid-sparing agents. Prefer-
ences for different IMT classes were assessed in this study.
The results showed that the frequency of IMTapplications
was 25.0 % (CI = 0.155–0.37) for mycophenolate mofetil,
32.4 % (CI = 0.22–0.45) for anti-TNF, 38.2 % (CI = 0.27–
0.51) for cyclosporine, and 36.8 % (CI = 0.25–0.49) for
others. This shows that the proportion of IMT drugs pre-
scribed by ophthalmologists is similar across different
types of IMT. In contrast to our findings, a survey of US
uveitis specialists showed that methotrexate was preferred
for initial management of uveitis while mycophenolate
mofetil was preferred for intermediate and posterior uve-
itis; the primary reason for not prescribing cyclosporine
was safety and tolerability. Another practice pattern sur-
vey of US uveitis specialists, Canadian specialists use
cyclosporine more frequently, while mycophenolate mofe-
til was used less often [19].
Limitations
Several limitations of this study should be noted. First,
the survey was set up such that mandatory responses to
questions were not required and, therefore, incomplete
data was recorded in the form of non-responses, result-
ing in incomplete data analysis and interpretation. A
second limitation of this study is sampling bias, where
physicians who responded to the study may feel more
proficient in the management of uveitis leading to an
overestimation of the proportion of self-reported
awareness of guidelines and proportion of total correct
responses. Therefore, the management patterns of uve-
itis among Canadian ophthalmologists may not be ac-
curately represented through this survey. Third, the low
number of uveitis specialists included in this study
limits the statistical analyses. Fourth, there were many
non-responses to questions regarding IMT applications
to provincial and private drug coverage and this might
have been due to respondents not making any IMT ap-
plications and the survey questions did not assess this
directly. Lastly, it has been reported that indicators for
treatment vary among uveitis specialists despite guide-
lines, and this variation is even greater among non-uveitis
specialists. As such, this may overestimate the observed
variability in responses to the survey [20].
Conclusions
In conclusion, the awareness and utilization of the uveitis
management guidelines among Canadian ophthalmologists
can be improved. Furthermore, recent graduates were less
likely to identify cases of uveitis where treatment with IMT
is indicated. They were also more likely to manage uveitis
with corticosteroid injections and less likely to refer pa-
tients to uveitis specialists. When use of IMT is necessary,
the majority of ophthalmologists indicated that they would
refer patients to uveitis specialists or other internists such
as rheumatologists and dermatologists. Few applications
for IMT were made by ophthalmologists, and majority of
these applications were sent by non-ophthalmologists.
Cumulatively, these results suggest the need for further
education of Canadian ophthalmologists regarding uve-
itis treatment guidelines and the need to increase the
number of uveitis specialists in Canada.
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